Details:
This agreement provides RSF Bio with Sanofi’s rights to Ataciguat. With this license, RSF Bio will have the rights it needs to continue development of Ataciguat through clinical trials in the United States and potentially in select international countries.
Lead Product(s): Ataciguat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: HMR1766
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Rancho Santa Fe Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 17, 2021
Details:
Acticor Biotech is developing glenzocimab (ACT017), a humanized monoclonal antibody (mAb) fragment directed against a novel target of major interest, platelet glycoprotein VI (GPVI). Glenzocimab inhibits platelet binding to the thrombus.
Lead Product(s): Glenzocimab
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACT017
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: University of Birmingham
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 22, 2022
Details:
TOTUM•070 is a combination of plant extracts, with no phytosterol or red yeast rice content. TOTUM•070 is being developed with a view to obtaining a proprietary health claim relating to the reduction of blood LDL cholesterol, a risk factor for cardiovascular diseases.
Lead Product(s): Totum•070
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Totum•070
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: TP ICAP Midcap
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 09, 2022
Details:
This innovative study is the first to characterize the metabolites of TOTUM•070 in humans and their mode of action in the liver in a population of 10 healthy volunteers. TOTUM•070 was tested at its clinical daily dose (5g), used also in the Phase II HEART clinical trial.
Lead Product(s): Totum•070
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Totum•070
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2022
Details:
The main objective of this clinical study is to evaluate the efficacy of a 5g daily dose of TOTUM-070 and to confirm its safety. HEART results will support the application for a proprietary health claim related to the reduction of LDL-cholesterol.
Lead Product(s): TOTUM-070
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TOTUM-070
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2021
Details:
The clinical study HEART on TOTUM-070, a Phase II randomized placebo-controlled and double blind study, has just been initiated in accordance with the road map, the study protocol having been submitted to the French health authorities.
Lead Product(s): TOTUM-070
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TOTUM-070
Highest Development Status: Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020